文献速递胸部肿瘤骨软组织肉瘤与黑色素瘤支持与姑息治疗

癌症辅助免疫治疗的成本效果:系统综述

Cost-Effectiveness of Adjuvant Immunotherapy in Cancer Treatments: A Systematic Review.
PubMed 文献 · JAMA Oncol · 2026-01-01

该系统综述检索2015年1月至2025年1月发表的经济学评价,纳入69项辅助免疫治疗的成本效果或成本效用分析。多数研究报告辅助免疫治疗组获得更高QALY/LY增益(63项,91%),超过半数(40项,58%)认为具有成本效果,但结果因癌种、模型假设、药价和各国阈值而异。

要点

  • 辅助免疫治疗多报告QALY/LY增益,但成本效果结论因癌种、药价和阈值而异。
  • 46项(67%)评价一线单药检查点抑制剂,Markov模型和EQ-5D最常用。
  • 建议基于价值选择性采用辅助免疫治疗,并推动透明标准化的经济学评价。

核心结论

  • 辅助免疫治疗常与有意义的QALY/LY改善相关,在高危或一线治疗场景中常被认为具有成本效果。
  • 其经济价值仍取决于具体情境,受治疗策略、药品成本和模型假设影响。
  • 结果支持基于价值选择性采用辅助免疫治疗,并强调需要透明、标准化的经济学评价以指导报销和政策决策。

研究设计与样本

  • 系统综述检索PubMed、Scopus、Embase和Web of Science,纳入2015年1月1日至2025年1月31日发表的全经济学评价。
  • 纳入任何癌种辅助免疫治疗的成本效果或成本效用分析,共纳入69项研究。
  • 采用2023年健康经济质量评价标准评估方法学质量,因卫生系统异质性采用叙述性综合。

主要发现

  • 纳入69项研究,最常见为非小细胞肺癌和黑色素瘤。
  • 46项(67%)评价一线单药检查点抑制剂治疗。
  • 63项(91%)报告辅助免疫治疗组QALY/LY增益更高,尤其见于非小细胞肺癌、企业资助研究和联合方案。
  • 40项(58%)评价认为辅助免疫治疗具有成本效果,但结果因癌种、模型假设、药品定价、资助机构和各国阈值而异。
  • Markov模型为主要分析方法(46项,67%),EuroQol 5 Dimensions为最常用健康效用工具(56项,81%)。

关键数值与推荐

  • 63项(91%)研究报告辅助免疫治疗组QALY/LY增益更高。
  • 40项(58%)评价认为辅助免疫治疗具有成本效果。
  • 46项(67%)采用Markov模型,56项(81%)使用EuroQol 5 Dimensions。

临床怎么用

  • 在高危或一线治疗场景中可考虑辅助免疫治疗,但需结合当地药品价格和阈值判断经济价值。
  • 报销和政策决策应参考透明、标准化的经济学评价,并关注模型假设和资助来源的影响。

局限性

  • 因卫生系统异质性,结果采用叙述性综合而非定量合并。
  • 成本效果结论受模型假设、药品定价、资助机构和各国阈值影响,需谨慎外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Adjuvant immunotherapy is increasingly integrated into cancer care to reduce recurrence and improve survival. However, its high cost raises critical concerns regarding affordability and economic value across diverse health system contexts. OBJECTIVE: To synthesize published economic evaluations of adjuvant immunotherapy and assess cost-effectiveness outcomes, quality-adjusted life-year (QALY)/life-year (LY) gains, and methodologic approaches. EVIDENCE REVIEW: A systematic search was conducted of PubMed, Scopus, Embase, and Web of Science for full economic evaluations published between January 1, 2015, and January 31, 2025. Eligible studies included cost-effectiveness or cost-utility analyses of adjuvant immunotherapy across any cancer type. Data were extracted on cancer type, treatment strategy (single vs combination therapy), treatment line, model structure, health utility instruments, funding sources, and cost-effectiveness outcomes. Methodologic quality was appraised using the Criteria for Health Economic Quality Evaluation 2023. Due to heterogeneity of health systems, findings were narratively synthesized. FINDINGS: The analysis included 69 studies covering a range of cancer types, most frequently non-small cell lung cancer and melanoma. Of these, 46 (67%) evaluated first-line therapy with single-agent checkpoint inhibitors. Higher QALY/LY gains were consistently reported among the adjuvant immunotherapy group (63 [91%]), particularly for non-small cell lung cancer, industry-funded studies, and combination regimens. More than half of the evaluations (40 [58%]) concluded that adjuvant immunotherapy was cost-effective, although results varied by cancer type, model assumptions, drug pricing, funding organizations, and country-specific thresholds. Markov modeling was the dominant analytic approach (46 [67%]) and EuroQol 5 Dimensions was the most commonly used health utility instrument (56 [81%]). CONCLUSIONS AND RELEVANCE: This systematic review found that adjuvant immunotherapy was frequently associated with meaningful QALY/LY improvements and was often considered cost-effective in high-risk or first-line settings. However, economic value remains context-specific, shaped by treatment strategy, drug costs, and modeling assumptions. These findings support the selective, value-based adoption of adjuvant immunotherapy and underscore the need for transparent, standardized economic evaluations to guide reimbursement and policy decisions.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Mahumud RA, Chen Y, Shahjalal M, et al. Cost-Effectiveness of Adjuvant Immunotherapy in Cancer Treatments: A Systematic Review. JAMA Oncol. 2026. PMID: 41569596. doi:10.1001/jamaoncol.2025.6080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。